A cease-trade order has been issued to the directors and key officers of Canada-based Valeant Pharmaceuticals International (TSX: VRX) after the company failed to file its annual financial statements on time, it has emerged.
Valeant said it requested the temporary order pending its filing of audited financial statements for 2015.
A spokesperson said: “As previously announced, Valeant asked the Autorité Des Marches Financiers (AMF), the company’s principal regulator in Canada, for a management cease-trade order pending filing of the audited annual financial statements for the year ended December 2015, the related management’s discussion and analysis, certificates of its CEO and CFO and its 2015 Form 10-K.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze